Vilazodone
- Generic Name
- Vilazodone
- Brand Names
- Viibryd
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27N5O2
- CAS Number
- 163521-12-8
- Unique Ingredient Identifier
- S239O2OOV3
- Background
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.
- Indication
用于治疗成人重度抑郁症（MDD）。
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- -
Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Pharmacology Research Institute
- Registration Number
- NCT00290914
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Genaissance Pharmaceuticals
- Target Recruit Count
- 410
- Registration Number
- NCT00285376
- Locations
- 🇺🇸
University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders Section, Philadelphia, Pennsylvania, United States
🇺🇸University of Utah health Services Center Dept. of Psychiatry Mood and Anxiety Disorders, Salt Lake City, Utah, United States
🇺🇸Pharmacology Research Institute, Riverside, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.